Home - Products - Wnt/Notch/Hedgehog - Wnt/beta/catenin - Nesuparib

Nesuparib

CAS No. 2055357-64-5

Nesuparib( —— )

Catalog No. M35605 CAS No. 2055357-64-5

Nesuparib (JPI-547/OCN-201) is a potent PARP inhibitor with inhibitory effects on PARP and TNKS1.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	137	Get Quote
5MG	211	Get Quote
10MG	337	Get Quote
25MG	586	Get Quote
50MG	799	Get Quote
100MG	1062	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Nesuparib
Note

Research use only, not for human use.
Brief Description

Nesuparib (JPI-547/OCN-201) is a potent PARP inhibitor with inhibitory effects on PARP and TNKS1.
Description

Nesuparib is a potent inhibitor of PARP. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease (extracted from patent WO2016200101A2).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Wnt/Notch/Hedgehog
Target

Wnt/beta/catenin
Recptor

Wnt/beta-catenin | PARP
Research Area

——
Indication

——

Chemical Information

CAS Number

2055357-64-5
Formula Weight

400.48
Molecular Formula

C23H24N6O
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : ≥ 62.5 mg/mL (156.06 mM )
SMILES

O=c1[nH]c2cc(CN3CCN(CC3)c3ccc(cn3)C#N)ccc2c2NCCCc12
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Delafloxacin

Delafloxacin (RX-3341, ABT-492) is a fluoroquinolone antibiotic agent. It has potent inhibitory against levofloxacin-resistant Streptococcus pneumoniae strains (MIC: 0.0078-0.125 μg/ml).
β-catenin modulator ...

β-catenin modulator IIa-661 is a small molecule inhibitor of the Wnt pathway with antitumour activity.
Vantictumab

Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.

Sign In Join Free